Trial
NCT03906526
A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Celgene
Collaborators
—
Condition
Carcinoma, Squamous Cell
Intervention
VTX-2337
Why stopped
Business objectives have changed
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-24